title: Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.
abstract: The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic large-cell lymphoma that sustains complete response after 3 years of crizotinib monotherapy.
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: Carolina Valeria
authors.initials: CV
authors.lastname: Mahuad
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: María de Los Ángeles Vicente
authors.initials: Mde L
authors.lastname: Repáraz
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: Marta E
authors.initials: ME
authors.lastname: Zerga
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: María Florencia
authors.initials: MF
authors.lastname: Aizpurua
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: Claudia
authors.initials: C
authors.lastname: Casali
authors.affiliation: Service of Hematology, Department of Internal Medicine, Hospital Alemán , Buenos Aires, Argentina.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Garate
keywords: Lymphoma; anaplastic; anaplastic lymphoma kinase; crizotinib; large-cell